Argos, Argolis Mar 9, 2026 (Issuewire.com) - Stelios Tzellos, Ph.D., marks more than a decade working across pharmaceutical analytics and oncology forecasting, building a career that bridges molecular biology and commercial strategy. His professional path reflects a steady progression from academic research at Imperial College London to analytics and forecasting roles at GlobalData, IQVIA, and AstraZeneca.
Dr. Tzellos began his career in laboratory research, completing undergraduate and Master’s degrees in Biochemistry before earning a Ph.D. in Molecular Biology from Imperial College London. His doctoral work examined Epstein-Barr virus gene regulation, with a focus on the EBNA-2 gene and the biological differences between viral strain types. His research led to multiple peer-reviewed publications, including a first-author paper in the Journal of General Virology in 2014.
Following the completion of his doctorate, Dr. Tzellos transitioned into pharmaceutical analytics, applying scientific training to market evaluation and forecasting. At GlobalData, he worked as an Oncology and Haematology Analyst, contributing to disease landscape reports and drug sales projections. His analysis included commentary on treatment adoption trends and the commercial impact of premium-priced oncology therapies.
He later joined IQVIA, where he continued working in analytics roles focused on data interpretation and forecasting methodology within the life sciences sector. His responsibilities included evaluating pipeline performance, analyzing clinical data in a commercial context, and supporting strategic planning through quantitative modeling.
At AstraZeneca, Dr. Tzellos further expanded his focus on oncology analytics, contributing to commercial insights that connect scientific understanding with long-term market strategy. Across each stage of his career, oncology has remained a central theme, reflecting both his scientific background and his professional specialization.
Over the past decade, pharmaceutical forecasting has evolved significantly. Increased data availability, expanding oncology pipelines, and more complex treatment landscapes have raised expectations for analytical rigor. Dr. Tzellos’ background in molecular biology provides a foundation for evaluating therapies not only from a revenue perspective but also through a scientific lens.
“Understanding the underlying biology strengthens forecasting decisions,” Dr. Tzellos has noted in previous commentary. “Scientific context adds depth to commercial projections.”
His work sits at the intersection of evidence and execution. Forecasting models must account for clinical trial data, regulatory timelines, market access dynamics, and real-world uptake patterns. This requires integration of scientific detail, structured quantitative analysis, and triangulation of multiple data points.
In addition to his industry roles, Dr. Tzellos has written publicly about forecasting methodology and the value of evidence-based thinking in pharmaceutical strategy. Through professional platforms such as Medium, he has explored topics including data integration, uncertainty in projections, and the importance of methodological transparency.
The milestone of more than ten years in pharmaceutical analytics reflects sustained engagement with oncology markets and evolving industry standards. From early research on viral gene regulation to commercial forecasting within global pharmaceutical organizations, Dr. Tzellos’ career illustrates the adaptability of scientific training across sectors.
Based in the United Kingdom, Dr. Tzellos continues to work in oncology-focused analytics roles while maintaining an active interest in the broader life sciences landscape. Outside of his professional work, he enjoys football, Formula 1, music, and home improvement projects.
Readers interested in his academic publications can find his peer-reviewed research indexed on PubMed.
About Stelios Tzellos
Stelios Tzellos, Ph.D., is a UK-based pharmaceutical analytics professional specializing in oncology forecasting and market strategy. He earned his degrees in Biochemistry and Molecular Biology from Imperial College London and has held roles at GlobalData, IQVIA, and AstraZeneca. His work focuses on integrating scientific expertise with commercial analytics to support data-driven decision-making in the pharmaceutical industry.
Media Contact
Stelios Tzellos *****@gmail.com http://steliostzellos.com
